In a multicentre , randomised , phase @ trial , we enrolled eligible patients aged @ years or older with acromegaly who were inadequately controlled ( @-point , @ h mean growth hormone concentration > @ g/L and insulin-like growth factor @ -LSB- IGF-@ -RSB- concentration > @ times the upper normal limit ) and had received @ mg octreotide long-acting repeatable or @ mg lanreotide ( Somatuline Autogel ; Ipsen , UK ) as monotherapy for @ months or longer .